政策与人文

订阅

MedSci主页 / 所有栏目 / 政策与人文

基金委与BMGF大挑战合作研究项目批准通知

2016-09-20 佚名 国家自然科学基金委员会

BMGF基金委
关注

  2016年度国家自然科学基金委员会（NSFC）与美国比尔及梅琳达•盖茨基金会（BMGF）大挑战合作研究项目批准通知 2016年度国家自然科学基金委员会（NSFC）与美国比尔及梅琳达•盖茨基金会（BMGF）大挑战合作研究项目共计受理有效全文申请书9项，经双方各自评审和共同协商，以下4个项目获得批准，项目执行期为4年（2017年1月1日—2020年12月31日）。

 

2016年度国家自然科学基金委员会（NSFC）与美国比尔及梅琳达•盖茨基金会（BMGF）大挑战合作研究项目批准通知

2016年度国家自然科学基金委员会（NSFC）与美国比尔及梅琳达•盖茨基金会（BMGF）大挑战合作研究项目共计受理有效全文申请书9项，经双方各自评审和共同协商，以下4个项目获得批准，项目执行期为4年（2017年1月1日—2020年12月31日）。

#

科学部编号

项目名称

申请人

单位名称

1

8161101485

基于gp41 MPER区中和表位天然结构的HIV疫苗的设计

陆路

复旦大学

2

8161101487

基于结构的艾滋疫苗设计

张林琦

清华大学

3

8161101490

利用生物标志物预测可短程治愈结核病患者的研究

高谦

复旦大学

4

8161101500

完整的抗结核人保护性抗体的分离和功能特征研究

Babak Javid

清华大学

请中方申请人在收到国家自然科学基金委员会签发的《项目批准通知》和《资助项目计划书填写通知》后，在基金委ISIS系统中按照通知的要求填写和提交项目计划书。

联系人：魏芹 刘秀萍

电　话：010-62325544；010-62325377

传　真：010-62327004

邮　箱：weiqin@nsfc.gov.cn; liuxp@nsfc.gov.cn

国际合作局

2016年9月19日

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1511424, encodeId=70f0151142485, content=<a href='/topic/show?id=b39142188fb' target=_blank style='color:#2F92EE;'>#基金委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42188, encryptionId=b39142188fb, topicName=基金委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ba10339852, createdName=12498474m33暂无昵称, createdTime=Thu Sep 22 11:03:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131925, encodeId=d1071319253b, content=牛人啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Sep 20 23:35:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131850, encodeId=9d1c1318508b, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131851, encodeId=73a813185147, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-22 12498474m33暂无昵称

    #基金委#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1511424, encodeId=70f0151142485, content=<a href='/topic/show?id=b39142188fb' target=_blank style='color:#2F92EE;'>#基金委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42188, encryptionId=b39142188fb, topicName=基金委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ba10339852, createdName=12498474m33暂无昵称, createdTime=Thu Sep 22 11:03:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131925, encodeId=d1071319253b, content=牛人啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Sep 20 23:35:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131850, encodeId=9d1c1318508b, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131851, encodeId=73a813185147, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 1dd8c52fm63(暂无匿称)

    牛人啊

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1511424, encodeId=70f0151142485, content=<a href='/topic/show?id=b39142188fb' target=_blank style='color:#2F92EE;'>#基金委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42188, encryptionId=b39142188fb, topicName=基金委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ba10339852, createdName=12498474m33暂无昵称, createdTime=Thu Sep 22 11:03:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131925, encodeId=d1071319253b, content=牛人啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Sep 20 23:35:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131850, encodeId=9d1c1318508b, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131851, encodeId=73a813185147, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 知难而进

    谢谢分享！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1511424, encodeId=70f0151142485, content=<a href='/topic/show?id=b39142188fb' target=_blank style='color:#2F92EE;'>#基金委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42188, encryptionId=b39142188fb, topicName=基金委)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ba10339852, createdName=12498474m33暂无昵称, createdTime=Thu Sep 22 11:03:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131925, encodeId=d1071319253b, content=牛人啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Sep 20 23:35:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131850, encodeId=9d1c1318508b, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131851, encodeId=73a813185147, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:55:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 知难而进

    继续关注！

    0